Introduction
Whilst Bray (1978) has seriously questioned the role of immune processes in cancer, and in malignant melanoma (MM) in particular, many believe that tumour-related antigens can be identified in MM (see Lewis 1977) . Since the reports of Jehn et al. (1970) and Carrel & Theilkaes (1973) that a tumour-related protein could be detected in the urine of patients with MM, we have presented our findings on the blood (Copeman & Elliott 1976 ) and on the urine (Volkers et al. 1978) of patients with MM, and on the blood (Copeman et al. 1973 ) and urine ) of a diverse group of patients with pigmentary disorders, with special emphasis on benign halo naevus (HN) ( Figure I ). Our recent studies on purified melanoma Figure I . Benign halo naevus: a central pigmented mole, with a depigmcnted halo. This halo has histopathological signs which are identical to those of vitiligo and it develops when the mole becomes infiltrated with lymphocytes and undergoes active resolution specific protein (MSP) have shown that it is a secretory product arising in the cytoplasm of aberrant melanocytes ) and here we propose a scheme which reconciles the production of this protein in benign and malignant pigmentary disorders with its complete absence in non pigmentary conditions including the closely related malignancy, neuroblastoma (Bennett et al. 1976 ).
Methods
Melanoma antibodies in serum were detected by using snap frozen malignant melanoma cells on microscope slides as a substrate tissue and a standard indirect immunofluorescence staining technique (Copeman et al. 1973) . Heterologous antihuman malignant melanoma antisera (RAMMA) was raised in the rabbit and then absorbed with suitable normal and cancerous tissues and insolubilized body fluids . Melanoma specific protein in urine was detected by a fluorescence inhibition procedure in which urine protein aliquots, coupled to insoluble beads using the carbodiimide reaction, were used to absorb out RAMMA (Bennett et at. 1976) .
Findings
Many of our earlier findings have already been reported in detail. To our MM studies in the blood (Copeman & Elliott 1976 ) and in the urine (Volkers et al. 1978) , and to those on HN in the blood (Copeman et al. 1973 ) and in the urine , we have added new information which is summarized in Tables I and 2.
In the blood (Table I) , the MM antibody was found in significant titre -according to the strict criteria of Elliott et al. (1973) -in patients with early MM and in increasing frequency as the clinical course of the disease progressed, but this titre fell and the antibodies disappeared as soon as the disease invaded regional lymph nodes or metastasized. In actively resolving benign HN, as in our earlier studies (Copeman et al. 1973) , the titre was found to be elevated, often to even higher titres than in MM. Similarly in the urine (Table 2) , in patients with benign HN undergoing active inflammatory resolution and in those with rapidly spreading vitiligo, MSP was almost invariably detected and usually with an incidence equal to those with malignant disease. But in MM the pattern differed from the results seen in the humoral antibody studies: MSP was found with increasing frequency as the disease course of MM advanced, so that after the cancer had metastasized, the incidence was at its greatest.
Discussion
MSP in the urine is found more readily as the course of MM advances. Its ability to inhibit antisera raised specifically against the cytoplasm of MM cells is the basis of the test used for detection, and so this protein would appear to originate in pigment cells that have altered (for example, undergone malignant change) rather than in normal melanocytes. It falls, therefore, into that group of proteins termed 'tumour markers'.
A protein unique to MM was isolated from tumour cyst fluid by Jehn et al. (1970) and is likely to have been released by cell death. However, using a mathematical model based on human serum albumin (mol.wt 67 000 daltons), a half-life of 10 days (in line with most acutephase reactants and tissue leakage proteins), and the diploid human liver cell, Bennett (1978) calculated that the human body does not contain enough pigment cells to enable a detectable quantity of MSP to arise from cell death alone in a patient with either a very extensive rapidly spreading vitiligo, or with numerous naevi developing haloes. Since these figures are based upon a very conservative model we are forced to accept that MSP must derive from a secretory product. Massive production of secretory proteins in other systems is well recognized as, say, in the synthesis of a 109 Type I haptoglobin (mol.wt 70 000 daltons) in 48 hours by healthy liver cells after a haemoglobin challenge or the secretion rate of 3 pg/cell/day Bence-Jones protein in multiple myeloma (Hobbs 1976) . Perhaps a similar relationship between tumour mass and protein level to that seen with Bence-Jones protein in myeloma may emerge in these pigmentary disorders. Definitive proof will await the quantitative assay now being developed, but the very high incidence of positive results in clinical stage III MM supports this hypothesis.
In considering specificity, it is encouraging that MSP has not been found in any condition other than certain pigment cell diseases . Although Carrel & Theilkaes (1973) did find a 'tumour marker' protein associated with other neural tumours, we not only' failed to detect MSP in patients with neuroblastoma but described a similar, immunologically distinct, protein associated with that disease (Bennett et al. 1976) . To find MSP in the benign diseases of halo naevus and vitiligo therefore surprised us, particularly as the number of cells affected in the latter disorder is small. The situation was resolved for halo naevus when we showed that heterologous and autologous antimelanoma antisera and the sera from patients with halo naevus reacted with the cytoplasm of the cells within a halo naevus and seemingly the complete cluster of the cells in the naevus were all affected (Bennett &' Copeman 1979) . The altered cytoplasmic component of MM cells we conclude is shared thus by the 'condemned' cells of the actively resolving halo naevus. With vitiligo, our problem is to define the areas on the skin surface where melanocytes are undergoing mutation. However, Herz et al. (1977) , using a complement enhancement technique, recently found that the sera of patients with vitiligo possessed a type of antimelanoma antibody, as Langhof et al. (1965) claimed, although it was only detected when the vitiligo was associated with organ or cell-specific autoimmune disease.
Pigment cells seem to suffer unique changes that (1) result in immunologically distinct cells, and (2) are shared between malignant and benign conditions. The production of a single mutant protein, as assessed by various physicochemical characterizations , would indicate that the pigment cell can undergo only a restricted. mutation and, furthermore, that this is common to each of the pigment diseases we have studied. The initial changes would appear to be the same whether the mutagen be ultraviolet (u.v.) , commonly implicated in the aetiology of malignant melanoma, endogenous byproducts of melanin synthesis, as in vitiligo (Lerner 1971) , or biological 'toxins' (perhaps initially viral) as in lichen planus. We envisage that whilst such mutagens affect a common pathway, these effects may still vary in intensity and produce a gradation from lethal mutation and cell death in vitiligo through the chaos of halo naevus and its depigmented halo of dead melanocytes, to the anarchy of malignant melanoma where a successful cell mutation gives rise to a monoclone that flourishes prolifically (indeed catastrophically) by competing with the established order to the detriment of the host.
Whilst this single concept ( Figure 2 ) interprets our findings in malignant and benign pigment cell diseases, the question of the origin of MSP remains unsolved. The antisera used in our studies do not react with the cells of normal moles , so that normal cells do not provide the source of the antigen, whilst the lack of common determinants between urinary neuroblastoma protein and MSP (both arising from tumours of neural crest cells) would argue against de noto production of a fetal protein. Figure 2 . Influences, known and unknown, impinge upon the healthy skin secretory melanocyte. It is postulated that in due time the pigment cell may change its nature and this mutation will be: (I) lethal to itself as in vitiligo, or create disorderly behaviour as in MM: (2) Immunogenic, a reflection of which ean be detected in the blood and urine by the tests descri bed
The concept of an entirely new secretory protein originating from a benign mutation is not an idea likely to find immediate support. To substantiate our claims fetal tissues must be searched for precursors and melanoma cells examined to identify the organelles from which MSP arises. The fine structure of malignant lentigo, the least aggressive MM, most closely resembles that of the normal melanocyte (Hunter, Zaynoun et al. 1978) , and in this condition the incidence of MSP is the least. Well-marked histochemical ultrastructural differences have been noted from tumour to tumour in MM (Hunter, Paterson & Fairley 1978) .
Perhaps this variability in structure and apparent function of the damaged melanocytes reflects the different responses which patients and their melanocytes experience after being subjected to such agents as ultraviolet.
Conclusions
The similar immunological findings in the blood and in the urine of MM and benign HN (Tables I and 2 ) are postulated as being the product of similar mutations to the melanocytes, and a model is presented (Figure 2) to account for such mutations. The more severe the mutagenic dose, the more likely that a mutation lethal to the melanocyte itself will occur. In this respect our model is entirely consistent with the proposition of Bray (1978) that high doses of sunlight u.v. result in a milder form of MM in Australia than occurs with the continuous small doses ofu.v. experienced in northern climes.
S~mmary
Melanoma specific protein (MSP) has been shown to be immunologically related to the cells of malignant melanoma (MM) but not to those of any other cancer. Curiously, it is found in the urine of patients with certain benign pigmentary dermatoses in which the secretory melanocytes are dying; notably in halo naevus (HN) which is actively regressing and developing a depigmented surround, and in vitiligo when the depigmented areas are extending rapidly.
These two extremes of condition are reconciled by the postulation that the melanocytes undergo a change and that this mutation is similar, whether the disease is classed as malignant or benign. Paradoxically, to the patient's melanocytes the disease process is more catastrophic in the case of HN or vitiligo where the cells die and disappear, than in MM where the cells not only survive but proliferate successfully.
